IMCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunocore Holdings PLC (IMCR) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this moment. While the company has shown positive revenue and net income growth in its latest quarter, the technical indicators and options data suggest a lack of strong upward momentum or significant positive sentiment. Additionally, there are no recent news catalysts or congress trading activity to support immediate action. Analysts' ratings are mixed, with some optimism, but the stock's near-term price trend and sentiment do not align with a strong buy recommendation.
The technical indicators for IMCR are neutral. The MACD histogram is slightly positive (0.0685), but contracting, and the RSI is at 41.751, indicating no clear overbought or oversold condition. The moving averages are converging, and the stock is trading near its support level (S1: 31.016) with resistance at R1: 34.37. Overall, there is no strong technical signal for a buy.
Revenue increased by 24.30% YoY in Q4
Net income improved by 26.46% YoY.
UBS recently upgraded the stock to 'Buy' with a price target of $55, citing improving biotech fundamentals.
Gross margin dropped by 2.21% YoY.
High options put-call ratios indicate bearish sentiment.
No recent news or significant trading trends from hedge funds or insiders.
Congress trading data shows no recent activity.
In Q4 2025, Immunocore's revenue grew by 24.30% YoY to $104.48M, and net income improved by 26.46% YoY to -$30.06M. EPS also improved by 25.53% YoY to -0.59. However, gross margin declined by 2.21% YoY to 97.41%. While the company is showing growth, it remains unprofitable.
Analysts have mixed ratings on IMCR. UBS upgraded the stock to 'Buy' with a $55 price target, citing improving biotech fundamentals. Mizuho raised its price target to $38 but maintained a 'Neutral' rating. Morgan Stanley raised its target to $40 but kept an 'Equal Weight' rating. The consensus reflects cautious optimism, but not a strong buy signal.
